← Human Trials & Peer-Reviewed Studies
Relationship Between Oral Semaglutide Tablet Erosion and Pharmacokinetics: A Pharmacoscintigraphic Study
Plain-language guide to PMID 33750044 (2021): open-label randomized controlled trial study of Semaglutide in 26 men.
Key Facts
- PMID
- 33750044
- Journal
- Clinical pharmacology in drug development
- Year
- 2021
- Study type
- Randomized Controlled Trial
- Authors
- Baekdal TA et al. (5 authors)
- DOI
- 10.1002/cpdd.938
What This Study Did, in Plain Language
What Was Tested
Researchers studied Semaglutide in this randomized controlled trial publication.
Semaglutide, a glucagon-like peptide-1 (GLP-1) analogue, has been coformulated in a tablet with the absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC).
Complete tablet erosion (CTE) occurred in the stomach irrespective of water volume administered with the tablet (primary end point).
Who Took Part
The study group was 26 men.
The age groups tagged for this paper are adults and middle-aged adults, men only.
How the Study Was Run
The design is described as randomized, open-label and crossover.
Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.
Nothing was hidden in this open-label Semaglutide study: the men and staff both knew the treatment.
Each person switched between Semaglutide and the comparison at some point, usually with a gap in between.
Tablet erosion and gastrointestinal transit were assessed by gamma scintigraphy.
Semaglutide and SNAC plasma concentrations were measured until 24 and 6 hours, respectively, after administration.
What Was Measured
Complete tablet erosion (CTE) occurred in the stomach irrespective of water volume administered with the tablet (primary end point).
Topics PubMed links to this paper include Area Under Curve, Caprylates, Fasting, Glucagon-Like Peptides, Hypoglycemic Agents, Radionuclide Imaging and Tablets.
Author keywords: gastric absorption, gastrointestinal transit, glucagon-like peptide-1, scintigraphy and sodium N-(8-[2-hydroxybenzoyl] amino) caprylate.
What This Means in Plain Language
The paper is a randomized, open-label and crossover study of Semaglutide in 26 men.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2021 (Clinical pharmacology in drug development), a journal based in United States.
More context: the Semaglutide compound page, all human trials.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.